JP2017507139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507139A5 JP2017507139A5 JP2016552595A JP2016552595A JP2017507139A5 JP 2017507139 A5 JP2017507139 A5 JP 2017507139A5 JP 2016552595 A JP2016552595 A JP 2016552595A JP 2016552595 A JP2016552595 A JP 2016552595A JP 2017507139 A5 JP2017507139 A5 JP 2017507139A5
- Authority
- JP
- Japan
- Prior art keywords
- maintenance doses
- antagonist
- laba
- ics
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 18
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 18
- 238000012423 maintenance Methods 0.000 claims 18
- 239000005557 antagonist Substances 0.000 claims 13
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 12
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 11
- 229940125389 long-acting beta agonist Drugs 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 208000006673 asthma Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000037874 Asthma exacerbation Diseases 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020036331A JP6893265B2 (ja) | 2014-02-21 | 2020-03-04 | Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943019P | 2014-02-21 | 2014-02-21 | |
| US61/943,019 | 2014-02-21 | ||
| EP14306413 | 2014-09-15 | ||
| EP14306413.7 | 2014-09-15 | ||
| US201462077669P | 2014-11-10 | 2014-11-10 | |
| US62/077,669 | 2014-11-10 | ||
| PCT/US2015/016852 WO2015127229A1 (en) | 2014-02-21 | 2015-02-20 | Methods for treating or preventing asthma by administering an il-4r antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036331A Division JP6893265B2 (ja) | 2014-02-21 | 2020-03-04 | Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507139A JP2017507139A (ja) | 2017-03-16 |
| JP2017507139A5 true JP2017507139A5 (https=) | 2018-03-22 |
| JP6673840B2 JP6673840B2 (ja) | 2020-03-25 |
Family
ID=51570453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552595A Active JP6673840B2 (ja) | 2014-02-21 | 2015-02-20 | Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
| JP2023139455A Active JP7636487B2 (ja) | 2014-02-21 | 2023-08-30 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
| JP2025020415A Active JP7842268B2 (ja) | 2014-02-21 | 2025-02-12 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023139455A Active JP7636487B2 (ja) | 2014-02-21 | 2023-08-30 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
| JP2025020415A Active JP7842268B2 (ja) | 2014-02-21 | 2025-02-12 | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10137193B2 (https=) |
| EP (3) | EP3107575B1 (https=) |
| JP (3) | JP6673840B2 (https=) |
| KR (4) | KR102368450B1 (https=) |
| CN (1) | CN106232140A (https=) |
| AU (3) | AU2015218808B2 (https=) |
| CA (2) | CA3249780A1 (https=) |
| ES (2) | ES2897631T3 (https=) |
| HU (1) | HUE065844T2 (https=) |
| IL (1) | IL315136A (https=) |
| MX (2) | MX384192B (https=) |
| PL (2) | PL3973987T3 (https=) |
| PT (2) | PT3973987T (https=) |
| RU (1) | RU2713406C2 (https=) |
| WO (1) | WO2015127229A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| JP6306588B2 (ja) * | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| AU2014284235C1 (en) * | 2013-06-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| EP3838271B1 (en) | 2013-07-12 | 2025-09-03 | Areteia Therapeutics, Inc. | Treating elevated levels of eosinophils and/or basophils |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| KR102695088B1 (ko) | 2014-02-28 | 2024-08-16 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| US20180056018A1 (en) * | 2016-08-31 | 2018-03-01 | Cephalon, Inc. | Inhalation Systems, Devices and Methods |
| ES2994774T3 (en) | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| RU2759630C2 (ru) | 2016-09-22 | 2021-11-16 | Ридженерон Фармасьютикалз, Инк. | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r |
| TWI857389B (zh) * | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| ES3052989T3 (en) * | 2017-04-13 | 2026-01-16 | Regeneron Pharma | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
| US11850283B2 (en) | 2017-06-27 | 2023-12-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for asthma |
| EP3645009A4 (en) | 2017-06-27 | 2021-03-31 | The Ohio State Innovation Foundation | LIPONUCLEOTIDE THERAPY FOR COPD |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| KR102694419B1 (ko) * | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| BR112020020387A2 (pt) | 2018-05-13 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r |
| AU2019302642B2 (en) | 2018-07-10 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Modifying binding molecules to minimize pre-existing interactions |
| CN110872349A (zh) * | 2018-09-04 | 2020-03-10 | 三生国健药业（上海）股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
| CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| CN116813770A (zh) * | 2018-12-27 | 2023-09-29 | 中山康方生物医药有限公司 | 抗人il-4ra的抗体及其用途 |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| SG11202111255YA (en) * | 2019-05-01 | 2021-11-29 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| WO2021011614A1 (en) * | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| JP7836754B2 (ja) | 2019-08-05 | 2026-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
| KR20220110829A (ko) | 2019-12-09 | 2022-08-09 | 사노피 바이오테크놀로지 | 디지털 식별된 il-4/il-13 관련 장애의 치료 방법 |
| CN113797331A (zh) * | 2020-06-16 | 2021-12-17 | 三生国健药业（上海）股份有限公司 | 一种稳定的抗IL-4Rα单克隆抗体液体制剂 |
| EP4192453A4 (en) * | 2020-08-05 | 2024-11-13 | Areteia Therapeutics, Inc. | USE OF DEXPRAMIPEXOLE TO TREAT MODERATE TO SEVERE ASTHMA |
| US20220169739A1 (en) * | 2020-10-05 | 2022-06-02 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| KR20240053586A (ko) * | 2021-08-26 | 2024-04-24 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항il4r 항체의 의약 조성물 및 그의 사용 |
| CN117368487A (zh) * | 2023-09-28 | 2024-01-09 | 首都医科大学附属北京同仁医院 | 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| MXPA06004853A (es) | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
| CA2550933A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| AU2005219837A1 (en) | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 sepecific polypetides and therapeutic uses thereof |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| JP2009523460A (ja) * | 2006-01-24 | 2009-06-25 | ドマンティス リミテッド | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| BRPI0822099A2 (pt) * | 2007-12-21 | 2017-05-23 | Medimmune Ltd | membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação |
| EP2376656A4 (en) | 2008-12-01 | 2012-05-16 | Cincinnati Children S Hospital Medical Ct | METHOD AND DETERMINATION OF THE EFFECTIVENESS OF A GLUCOCORTICOID TREATMENT OF EOSINOPHILIAN ESOPHAGITIS |
| WO2010120524A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
| WO2011156000A2 (en) * | 2010-06-07 | 2011-12-15 | Aerovance, Inc. | Use of il-4/il-13 antagonists to treat eosinophilic disorders |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| MX2013004212A (es) * | 2010-10-15 | 2013-09-02 | Medimmune Ltd | Terapias para mejorar la funcion pulmonar. |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| HK1201440A1 (en) * | 2011-11-01 | 2015-09-04 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| AU2014284235C1 (en) | 2013-06-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| KR102694419B1 (ko) * | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| US20220169739A1 (en) | 2020-10-05 | 2022-06-02 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
-
2015
- 2015-02-19 IL IL315136A patent/IL315136A/en unknown
- 2015-02-20 CN CN201580020533.9A patent/CN106232140A/zh active Pending
- 2015-02-20 US US14/627,728 patent/US10137193B2/en active Active
- 2015-02-20 PT PT211911201T patent/PT3973987T/pt unknown
- 2015-02-20 MX MX2016010854A patent/MX384192B/es unknown
- 2015-02-20 PT PT157089913T patent/PT3107575T/pt unknown
- 2015-02-20 CA CA3249780A patent/CA3249780A1/en active Pending
- 2015-02-20 PL PL21191120.1T patent/PL3973987T3/pl unknown
- 2015-02-20 PL PL15708991T patent/PL3107575T3/pl unknown
- 2015-02-20 AU AU2015218808A patent/AU2015218808B2/en active Active
- 2015-02-20 EP EP15708991.3A patent/EP3107575B1/en not_active Revoked
- 2015-02-20 KR KR1020167025669A patent/KR102368450B1/ko active Active
- 2015-02-20 KR KR1020227006120A patent/KR20220029765A/ko not_active Ceased
- 2015-02-20 HU HUE21191120A patent/HUE065844T2/hu unknown
- 2015-02-20 EP EP24150594.0A patent/EP4382164A3/en active Pending
- 2015-02-20 JP JP2016552595A patent/JP6673840B2/ja active Active
- 2015-02-20 WO PCT/US2015/016852 patent/WO2015127229A1/en not_active Ceased
- 2015-02-20 KR KR1020237041236A patent/KR20230167770A/ko not_active Ceased
- 2015-02-20 EP EP21191120.1A patent/EP3973987B1/en active Active
- 2015-02-20 ES ES15708991T patent/ES2897631T3/es active Active
- 2015-02-20 KR KR1020257035292A patent/KR20250154567A/ko active Pending
- 2015-02-20 ES ES21191120T patent/ES2977332T3/es active Active
- 2015-02-20 RU RU2016136364A patent/RU2713406C2/ru active
- 2015-02-20 CA CA2940295A patent/CA2940295A1/en active Pending
-
2016
- 2016-08-19 MX MX2021008113A patent/MX2021008113A/es unknown
-
2018
- 2018-10-11 US US16/157,708 patent/US20190125865A1/en not_active Abandoned
-
2020
- 2020-11-26 AU AU2020277191A patent/AU2020277191B2/en active Active
-
2021
- 2021-03-29 US US17/215,604 patent/US20210322546A1/en active Pending
-
2023
- 2023-08-30 JP JP2023139455A patent/JP7636487B2/ja active Active
-
2024
- 2024-06-06 AU AU2024203849A patent/AU2024203849A1/en active Pending
-
2025
- 2025-02-12 JP JP2025020415A patent/JP7842268B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507139A5 (https=) | ||
| RU2016136364A (ru) | Способы лечения или предупреждения астмы посредством введения антагониста il-4r | |
| JP2020002171A5 (https=) | ||
| JP2023162343A5 (https=) | ||
| JP2009541374A5 (https=) | ||
| CA2918105C (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| JP2021501169A5 (https=) | ||
| JP2018512435A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2015527364A5 (https=) | ||
| IL312710A (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor | |
| RU2017120437A (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| JP2016523863A5 (https=) | ||
| JP2017535547A5 (https=) | ||
| JP2006522830A5 (https=) | ||
| RU2012141556A (ru) | Способы и композиции для лечения болезни дего | |
| JP2009511480A5 (https=) | ||
| JP2017537105A5 (https=) | ||
| JP2019512472A5 (https=) | ||
| RU2019111921A (ru) | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r | |
| JP7572041B2 (ja) | 重症喘息を処置するための組成物および方法 | |
| EP3487881A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2025072440A5 (https=) | ||
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2007506681A5 (https=) |